New aspects of immunotherapy of leptomeningeal metastasis

Journal of Neuro-Oncology

Volumn 38, Issue 2-3, 1998, Pages 233-239

  Herrlinger, Ulrich ^a,b   Weller, Michael ^a   Schabet, Martin ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Immunotherapy; Interferon alpha; Interleukin 2; Intrathecal therapy; LAK cells; Leptomeningeal metastasis

Indexed keywords

ALPHA INTERFERON; FAS LIGAND; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANOREXIA; ATAXIA; AUTONOMIC DYSFUNCTION; BLOOD TOXICITY; BRAIN EDEMA; BRAIN TUMOR; CLINICAL TRIAL; CONFERENCE PAPER; DEMENTIA; FATIGUE; FEVER; GENETIC ENGINEERING; HUMAN; IMMUNOTHERAPY; INTRACRANIAL HYPERTENSION; INTRATHECAL DRUG ADMINISTRATION; LEPTOMENINX; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; MENINGIOMA; NAUSEA; NEUROTOXICITY; NONHUMAN; SEIZURE; SQUAMOUS CELL CARCINOMA; VACCINATION; VOMITING;

ANIMALS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MENINGEAL NEOPLASMS;

EID: 0031748219     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005948722912     Document Type: Conference Paper

References (50)

1. Bleyer WA, Byrne TN: Leptomeningeal cancer in leukemia and solid tumors. Curr Probl Cancer 12: 181-238, 1988
2. Weller M, Fontana A : The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21: 128-151, 1995
3. Tada M, de Tribolet N: Recent advances in immunobiology of brain tumors. J Neuro-Oncol 17: 261-271, 1993
4. Grimm EA, Crump III WL, Durett A, Hester JP, Lagoo-Denadalayan S, Owen-Schaub L: TGF-beta inhibits the in vitro induction of lymphokine-activated killing. Cancer Immunol Immunother 27: 53-38, 1988
5. 1. Cancer Res 52: 1386-1392, 1992
6. Moseley RP, Benjamin JC, Ashpole RD, Sullivan NM, Bullimore JA, Coakham HB, Kemshead JT: J Neurol Neurosurg Psychiatry 54: 260-265, 1991
7. Rosenberg SA: Principles and applications of biologic therapy. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer Principles and Practice of Oncology. 4th edition. J.B. Lippincott Co., Philadelphia, Pennsylvania 293-324, 1993
8. Jaeckle KA: Immunotherapy of malignant gliomas. Sem Oncol 21: 249-259, 1994
9. Tzeng J, Barth RF, Clendenon NR, Gordon W: Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin-2. Cancer Res 50: 4338-4343, 1990
10. Holladay FP, Choudhuri R, Heitz T, Wood GW: Generation of cytotoxic immune responses during the progression of a rat glioma. J Neurosurg 80: 90-96, 1994
11. Wood GW, Holladay FP, Heitz-Turner T, Bayer W: Treatment of recurrent malignant astrocytoma by reoperation, active immunization and cellular immunotherapy. Proc Annu Meet Am Assoc Cancer Res 36: A1332, 1995 (Abstract)
12. List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA: Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor α, interleukin 1β, interleukin 6, γ-interferon, and soluble interleukin 2 receptor (MW 55,000 Protein). Cancer Res 52: 1123-1128, 1992
13. Martin R, Schwulera U, Menke G, Rudolph W, Buch K, Fasold H, Lissner R, Thrun A, Krauseneck P, Bogdahn U: Interleukin-2 and blood brain barrier in cats: pharmacokinetics and tolerance following intrathecal and intravenous administration. Eur Cytokine Netw 3: 399-406, 1992
14. Rösener M, Schwulera U, Menke G, Thrun A, Lissner R, Krauseneck P, Bogdahn U, Martin R: Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. Eur Cytokine Netw 4: 189-195, 1993
15. Saris SC, Rosenberg SA, Friedman RB, Rubin JT, Barba D, Oldfield EH: Penetration of recombinant interleukin-2 across the blood-cerebro-spinal barrier. J Neurosurg 69: 29-34, 1988
16. Miyatake S, Yamashita J, Tokuriki Y, Yamasaki T, Nisihara T, Handa Y, Sugama K, Tsubai F, Hazama T, Handa H: Pharmacokinetics and toxicity of intrathecal administration of recombinant interleukin-2. Gan To Kagaku Ryoho 13: 2393-2398, 1986
17. Stewart JA, Bellinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF: Phase I trial of intraperitoneal recombinant interleukin-2/ lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50: 6302-6310, 1990
18. Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB: Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother 13: 49-54, 1993
19. Salmaggi A, Dufour A, Silvani A, Ciusani E, Nespolo A, Boiardi A: Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumors disseminating via CSF. Intern J Neurosci 77: 117-125, 1994
20. Schabet M, Herrlinger U, Buchholz R: CSF reaction pattern and neurotoxicity after intrathecal application of TNF-α and IFN-γ, or IL-2. J Neuro-Oncol 21: 67, 1994a (Abstract)
21. Herrlinger U, Buchholz R, Jachimczak P, Schabet M : Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2. J Neuro-Oncol 27: 193-203, 1996
22. Hayes R, Moore E, Pierz DM, Chen D, DaRosso R, Nirenberg A, Allen J: Interleukin-2 (IL-2)-inducible lymphokine-activated killer (LAK) activity arising in blood following IL-2/LAK therapy into the CSF compartment. Proc Annu Meet Am Soc Clin Oncol 12: A968, 1993
23. Allen J, Hayes R, DaRosso R, Nirenberg A, Moore E, Pierz D : Intraventricular interleukin-2 (IL-2)/lymphokine activated killer (LAK) cells for leptomeningeal metastases (LM) in pediatric brain tumors. Proc Annu Meet Am Soc Clin Oncol 12: A528, 1993
24. Moser RP, Bruner JM, Grimm EA: Biologic therapy for brain tumors. Cancer Bull 43: 117-126, 1991
25. Jaaskelainen J, Kalliomaki P, Paetau A, Timonen T: Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. J Immunol 142: 1036-1045, 1989
26. Schabet M, Ohneseit P, Herrlinger U, Buchholz R: Intrathecal treatment of B16-F10 melanoma leptomeningeal metastasis (LM) in nude rats with MTX, ACNU or the combination of IFN-gamma and TNF-alpha. Brain Pathol 4: 436, 1994b (Abstract)
27. Chong ASF, Scuderi P, Grimes WJ, Hersh EN: Tumor targets stimulate IL-2 activated killer cells to produce interferon-γ and tumor necrosis factor. J Immunol 142: 2133-2139, 1989
28. Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA: Interferon-γ and tumor necrosis factor have a role in tumor regression mediated by murine CD 8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647-658, 1991
29. McCutcheon IE, Baranco RA, Katz DA, Saris SC: Adoptive immunotherapy of intracerebral metastases in mice. J Neurosurg 72: 102-109, 1990
30. Saris SS, Spiess A, Lieberman DM, Shan Lin, Walbridge S, Oldfield EH: Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76: 513-519, 1992
31. Holladay FP, Heitz T, Wood GW: Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells. J Neurosurg 77: 757-762, 1992
32. Papadopoulos NE, Moser RP, Grimm E, Gerber D, Myers C, Leavens M, McCutcheon I, Leeds NE, Kumar AJ, Forman A, Legha S, Benjamin RS: Intrathecal use of recombinant interleukin-2 (rIL-2) in the treatment of leptomeningeal disease (LMD) from metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 14: A1307, 1995
33. Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y, Tsuda N, Takimoto H, Hayakawa T, Mogami H: An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien) 94: 47-52, 1988
34. Shimizu K, Tamura K, Yamada M, Okamoto Y, Miyao Y, Park K, Matsui Y, Hayakawa T, Takimoto H, Mogami H: Adoptive immunotherapy in patients with medulloblastoma by LAK cells. No To Shinkei 41: 991-995, 1989
35. Shimizu K, Okamoto Y, Miyao Y, Yamada M, Ushio Y, Hayakawa T, Ikeda H, Mogami H: Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 66: 519-521, 1987
36. Silvani A, Salmaggi A, Parmiani G, Boiardi A: Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report. Neurosurg 34: 1078-1081, 1994
37. Obbens EAMT, Feun LG, Leavens ME et al.: Phase I clinical trial of intralesional or intraventricular leukocyte interferon for intracranial malignancies. J Neuro-Oncol 3: 61-67, 1985
38. Meyers CA, Obbens EAMT, Scheibel RS, Moser RP: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 68: 88-92, 1991
39. Merchant RE, Ellison ED, Young HF: Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. J Neuro-Oncol 8: 173-188, 1990
40. Heimans JJ, Wagstaff J, Schreuder WO, Wolbers JG, Baars JW, Polman CH, Scharenberg JG, Scheper RJ, Palmer PA, Franks CR: Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. Surg Neurol 35: 244-247, 1991
41. Papa MZ, Vetto JT, Ettinghausen SE, Mule JJ, Rosenberg SA : Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin-2 in mice. Cancer Res 46: 5618-5623, 1986
42. Hanisch U, Seto D, Quirion R: Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2. J Neurosci 13: 3368-3374, 1993
43. Zalcman S, Green-Johnson JM, Murray L et al.: Cytokine-specific central monoamine alterations induced by interleukin-1, -2, and -6. Brain Res 643: 40-49, 1994
44. Meyers CA, Yung WKA: Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neuro-Oncol 15: 265-267, 1993
45. Vecht CJ, Keohane C, Menon RS, Henzen-Logmans SC, Punt CJA, Stoter G : Acute fatal leukoencephalopathy after interleukin-2 therapy. N Engl J Med 323: 1146-1147, 1990
46. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation by cytokines. J Clin Invest 94: 954-964, 1994
47. Herrlinger U, Kramm CM, Johnston KM, Louis DN, Reznikoff G, Dranoff G, Breakefield XO, Yu JS: Vaccination for experimental gliomas using GM-CSF transduced glioma cells. Cancer Gene Ther 4: 345-352, 1997
48. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K Hamada H : Intensified antitumor immunity by a cancer vaccine that prouces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56: 1828-1833, 1996
49. Yu JS, Burwick JA, Reznikoff G, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor melanoma cells. Hum Gene Ther 8: 1065-1072, 1997
50. Fahkrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914, 1996